CA3094988A1 - Thienopyrimidinone compounds - Google Patents

Thienopyrimidinone compounds Download PDF

Info

Publication number
CA3094988A1
CA3094988A1 CA3094988A CA3094988A CA3094988A1 CA 3094988 A1 CA3094988 A1 CA 3094988A1 CA 3094988 A CA3094988 A CA 3094988A CA 3094988 A CA3094988 A CA 3094988A CA 3094988 A1 CA3094988 A1 CA 3094988A1
Authority
CA
Canada
Prior art keywords
unsubstituted
substituted
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3094988A
Other languages
English (en)
French (fr)
Inventor
Kyle W.H. CHAN
Aparajita Hoskote Chourasia
Paul E. Erdman
Leah Fung
Imelda LAM
Frank Mercurio
Robert Sullivan
Eduardo Torres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioTheryX Inc
Original Assignee
BioTheryX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioTheryX Inc filed Critical BioTheryX Inc
Publication of CA3094988A1 publication Critical patent/CA3094988A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3094988A 2018-03-30 2019-03-28 Thienopyrimidinone compounds Abandoned CA3094988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650922P 2018-03-30 2018-03-30
US62/650,922 2018-03-30
PCT/US2019/024612 WO2019191451A1 (en) 2018-03-30 2019-03-28 Thienopyrimidinone compounds

Publications (1)

Publication Number Publication Date
CA3094988A1 true CA3094988A1 (en) 2019-10-03

Family

ID=66102328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3094988A Abandoned CA3094988A1 (en) 2018-03-30 2019-03-28 Thienopyrimidinone compounds

Country Status (8)

Country Link
US (1) US10584133B2 (https=)
EP (1) EP3774815A1 (https=)
JP (1) JP2021519786A (https=)
CN (1) CN112313236A (https=)
AU (1) AU2019243186A1 (https=)
CA (1) CA3094988A1 (https=)
TW (1) TW202003524A (https=)
WO (1) WO2019191451A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105335A1 (en) * 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
WO2021207530A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
WO2022255890A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
AU2012229300B2 (en) * 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
BR112015026297B1 (pt) * 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
RU2018117503A (ru) 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
CA3010801A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US11395820B2 (en) * 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
CA3043938A1 (en) * 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
US10406165B2 (en) * 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Also Published As

Publication number Publication date
TW202003524A (zh) 2020-01-16
AU2019243186A1 (en) 2020-10-15
US20190322682A1 (en) 2019-10-24
US10584133B2 (en) 2020-03-10
WO2019191451A1 (en) 2019-10-03
EP3774815A1 (en) 2021-02-17
JP2021519786A (ja) 2021-08-12
CN112313236A (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
US11400084B2 (en) Aminoamide compounds
US10584133B2 (en) Thienopyrimidinone compounds
CA3101335C (en) Fused thiophene compounds
US9938302B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
CA2986141C (en) Compounds targeting proteins, compositions, methods, and uses thereof
US11352338B2 (en) Substituted isoindolinones
US11236103B2 (en) Bifunctional compounds
WO2018169777A1 (en) Compounds targeting proteins, compositions, methods, and uses thereof
TW201835089A (zh) 靶向蛋白質之化合物、組合物、方法及其用途
WO2019173224A1 (en) Deuterated compounds and chimeras and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211123

FZDE Discontinued

Effective date: 20240405